Survey: NIH cuts push labs to brink, hit early-career scientists hard
A nationwide STAT survey of federally funded researchers reveals that, a year after Donald Trump’s return to the…
NIH invests $150 million in human-based research to reduce use of animal modelsÂ
Wednesday, March 18, 2026 New program will develop, validate and standardize research tools to develop more sophisticated and relevant models of disease. …
NIH Announces Major Policy Shift to End Use of Human Fetal Tissue in NIH-Supported Research
Thursday, January 22, 2026 Graph shows NIH spending on human fetal research over time. NIH The National Institutes…
SAMHSA cuts up to $1.9B in mental health, substance abuse grants
The federal agency that oversees mental health and addiction treatment on Tuesday made major cuts to programs across…
NIH Director: DEI grants restored by court order will not be renewed
Throughout the year, researchers have been heartened by legal decisions pushing back on directives from the National Institutes…
NIH agrees to reconsider frozen and denied DEI-related grants
The Trump administration has reached an agreement to reevaluate research projects left in bureaucratic limbo while a lawsuit…
The world needs an alternative to PubMed
In May the German National Library of Medicine announced its plan to develop an open, sustainable, and sovereign…
WWE Superstars visit pediatric research participants at NIH Clinical Center and The Children’s Inn
Friday, December 12, 2025 Pediatric research participants at the National Institutes of Health (NIH) Clinical Center and The…
Expanded umbilical cord blood transplant achieves 94% survival in severe aplastic anemia patients
Friday, December 12, 2025 NIH clinical trial shows promise for people with treatment-limited, life-threatening disorder. A clinical trial…
Researchers find genetic basis for important risk factor in blinding eye disease
Monday, December 8, 2025 International collaboration provides clues about important subtype of age-related macular degeneration. Image of a…
Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial
Although poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPis) and bevacizumab were approved as first-line maintenance for advanced ovarian cancer (OC),…
Secretary Kennedy Swears in Dr. Anthony Letai as Director of the National Cancer Institute
Monday, September 29, 2025 Anthony Letai, MD, Ph.D., was sworn in today as director of the National Cancer…